This isn't another generic insurance overview
Very convincing data and reassuring data in weight reduction and CV risk factors improvement Overall, less CV events than expected No significant difference in MACE-5 or MACE-3 but this was relatively small trial with only 1949 participants Confirmation of CV safety but larger CV trials will be needed to further explore protection against major cardiovascular event #retatrutide #obesity #CVevents #MACE #weightreduction #diabetes #lipids #bloodpressure #TRIUMP3trial Martin Haluzks Post -3 3 In TRIUMPH-3, both studied doses of retatrutide (9 mg and 12 mg) delivered substantial weight loss in adults with severe obesity and established cardiovascular disease, with or without type 2 diabetes
Side effects in detail Nausea and vomiting Nausea from Wegovy is a common side effect, occurring in 44% of adults and 42% of children 12 years and older
The 6-month oral glutathione RCT documented more than a twofold increase in natural killer (NK) cell cytotoxicity in the high-dose group, and liposomal glutathione raised NK cell cytotoxicity by up to 400% and lymphocyte proliferation by up to 60% in a pilot trial
Nonhematological benefits of iron
"A1 Reactive Astrocytes Activated by 2-chloroethanol Modulate M1 Microglia Polarization through Upregulating IL-1 and TNF-." Research Square
